JP2003502320A - アミロイドタンパク質凝集を阻害し、アミロイド沈着物を画像化する方法に使用するためのローダニン誘導体 - Google Patents

アミロイドタンパク質凝集を阻害し、アミロイド沈着物を画像化する方法に使用するためのローダニン誘導体

Info

Publication number
JP2003502320A
JP2003502320A JP2001503845A JP2001503845A JP2003502320A JP 2003502320 A JP2003502320 A JP 2003502320A JP 2001503845 A JP2001503845 A JP 2001503845A JP 2001503845 A JP2001503845 A JP 2001503845A JP 2003502320 A JP2003502320 A JP 2003502320A
Authority
JP
Japan
Prior art keywords
oxo
thioxo
benzylidene
thiazolidin
acetic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001503845A
Other languages
English (en)
Japanese (ja)
Inventor
コリーン・エリザベス・オージェリ−ソフラン
シェリー・アン・グレイズ
ラリー・クラスウェル・ウォーカー
智之 安永
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Warner Lambert Co LLC
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd, Warner Lambert Co LLC filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of JP2003502320A publication Critical patent/JP2003502320A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2001503845A 1999-06-10 2000-05-31 アミロイドタンパク質凝集を阻害し、アミロイド沈着物を画像化する方法に使用するためのローダニン誘導体 Pending JP2003502320A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13854499P 1999-06-10 1999-06-10
US60/138,544 1999-06-10
PCT/US2000/015069 WO2000076987A1 (en) 1999-06-10 2000-05-31 Rhodanine derivatives for use in a method of inhibiting amyloid protein aggregation and imaging amyloid deposits

Publications (1)

Publication Number Publication Date
JP2003502320A true JP2003502320A (ja) 2003-01-21

Family

ID=22482512

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001503845A Pending JP2003502320A (ja) 1999-06-10 2000-05-31 アミロイドタンパク質凝集を阻害し、アミロイド沈着物を画像化する方法に使用するためのローダニン誘導体

Country Status (8)

Country Link
EP (1) EP1192143A1 (pt)
JP (1) JP2003502320A (pt)
AU (1) AU5311800A (pt)
BR (1) BR0011441A (pt)
CA (1) CA2374616A1 (pt)
MX (1) MXPA01010490A (pt)
TR (1) TR200103562T2 (pt)
WO (1) WO2000076987A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020394A1 (es) 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
AU2003280188A1 (en) 2002-12-06 2004-06-30 Warner-Lambert Company Llc Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
US20060106077A1 (en) * 2003-07-18 2006-05-18 Pintex Pharmaceuticals, Inc. Pin1-Modulating compounds and methods of use thereof
JP2010518064A (ja) 2007-02-12 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション Ａｄおよび関連状態の治療のためのピペラジン誘導体
US8933075B2 (en) 2010-06-17 2015-01-13 Fuzians Biomedicals, Inc. Compounds useful as antiviral agents, compositions, and methods of use
CN106045986B (zh) * 2016-05-31 2019-12-06 广东工业大学 一种新型吩噻嗪衍生物及其制备方法与应用
CN106045987B (zh) * 2016-06-21 2019-04-23 广东工业大学 一种具有多功能近红外荧光磁性纳米微粒及其制备和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5740478A (en) * 1980-08-22 1982-03-06 Ono Pharmaceut Co Ltd Rhodanine derivative, its preparation and aldose reductase inhibitor containing rhodanine derivative
JPH01147476A (ja) * 1987-12-03 1989-06-09 Mita Ind Co Ltd 光導電性トナー
JPH01147462A (ja) * 1987-12-03 1989-06-09 Mita Ind Co Ltd 電荷発生材料およびその製法
US5143929A (en) * 1991-05-09 1992-09-01 Warner-Lambert Company 2-substituted thiazolidinone, oxazolidinone, and imidazolidinone derivatives of fenamates as antiinflammatory agents
EP0915090A1 (en) * 1992-09-10 1999-05-12 Eli Lilly And Company Compounds useful as hypoglycemic agents and for treating Alzheimer's disease
DE4318550A1 (de) * 1993-06-04 1994-12-08 Boehringer Mannheim Gmbh Aryliden-4-oxo-2-thioxo-3- thiazolidincarbonsäuren, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
AU1529297A (en) * 1996-01-24 1997-08-20 Warner-Lambert Company Method of imaging amyloid deposits
EP1128832A4 (en) * 1998-08-21 2003-03-05 Viropharma Inc COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND RELATED DISEASES
EP1117655A1 (en) * 1998-09-30 2001-07-25 Angelika Esswein Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders

Also Published As

Publication number Publication date
EP1192143A1 (en) 2002-04-03
TR200103562T2 (tr) 2002-04-22
AU5311800A (en) 2001-01-02
MXPA01010490A (es) 2005-05-27
WO2000076987A1 (en) 2000-12-21
BR0011441A (pt) 2002-07-16
CA2374616A1 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
US6001331A (en) Method of imaging amyloid deposits
AU777747B2 (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives
AU2008202626B9 (en) Thioflavin derivatives and their use in diagnosis and therapy of Alzheimer's disease
US6949575B2 (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
JP2003502320A (ja) アミロイドタンパク質凝集を阻害し、アミロイド沈着物を画像化する方法に使用するためのローダニン誘導体
JP2003502321A (ja) ローダニン誘導体ならびにアミロイドの阻害および画像化におけるその使用
EP1193260B1 (en) Phenoxazine analogs for the treatment of amyloidosis
US20040180943A1 (en) Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis
US20040197268A1 (en) Method of imaging amyloid deposits using substituted rhodanine derivatives
KR102426160B1 (ko) 알츠하이머 진단용 신규 형광화합물 및 이의 제조방법

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20041027

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20041027

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20041027

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050106